⊕ Medical information · we may earn if you start a program · editorial independence
FDA-approved Updated May 2026

Tirzepatide (Mounjaro / Zepbound)

Mounjaro · Zepbound

Dual GIP/GLP-1 receptor agonist with superior weight loss outcomes vs semaglutide.

Tirzepatide (Mounjaro / Zepbound) medication illustration

Explore all clinical reviewer profiles in our reviewer directory.

Freshness status: Fresh (26 days since review)

Clinical change log

Substantive medical-content updates are tracked here for transparency. See our methodology and disclosures.

  1. 2026-05-24T00:00:00Z UTC · Reviewed by Anika Reyes, MD

    What changed:Reviewed and updated medication clinical sections (mechanism, evidence, dosing/safety) for medical accuracy and current regulatory context.

    Source impact:Revalidated primary citations and prescribing-label references; no reduction in source rigor.

Clinical guidance, pricing, and eligibility vary by patient profile and prescribing context. We may earn from partner links, but compensation does not change editorial scoring. See our methodology and disclosures.

HIPAA Compliant Protected health data
503B Pharmacy Licensed compounding
Board Reviewed Medical oversight
FDA Registered Regulated facilities
Avg. weight loss 18–22%
Dose range 2.5–15 mg
Cadence Weekly

How it works

Tirzepatide is a dual GIP and GLP-1 receptor agonist. By activating both incretin pathways, it provides stronger appetite suppression and greater metabolic benefits than GLP-1 alone. [10] Head-to-head SURMOUNT trials showed up to 22.5% body weight loss at the 15mg dose.

Clinical trial evidence

SURMOUNT-1 [?]
Jastreboff et al., NEJM 2022 22.5% weight loss 2,539 participants, 72 weeks, 15 mg
SURMOUNT-2 [?]
Garvey et al., Lancet 2023 18.9% weight loss Patients with type 2 diabetes
SURMOUNT-3 [?]
With lifestyle intervention 21.1% additional loss ~26% total from baseline
SURMOUNT-4 [?]
84-week extension 26% total weight loss Continued efficacy without plateau
SURPASS-2 [?]
Frias et al., NEJM 2021 Glycemic superiority Head-to-head vs semaglutide
Full trial details
SURMOUNT-1 (Jastreboff et al., NEJM 2022, 2,539 participants): 22.5% mean body weight reduction at 72 weeks with 15 mg dose — the largest weight loss achieved by any anti-obesity medication at time of publication. [8] SURMOUNT-2: 18.9% weight loss in patients with type 2 diabetes, demonstrating efficacy is maintained in this population. [11] SURMOUNT-3 (with intensive lifestyle intervention): 21.1% additional weight loss after 72 weeks, for a total of ~26% from baseline. SURMOUNT-4 (84-week extension): up to 26% total weight loss, demonstrating continued efficacy without plateau over nearly 2 years. [9] SURPASS trials demonstrated cardiovascular safety and glycemic superiority over existing diabetes treatments. [12]
Bar chart comparing average weight loss: Semaglutide 15%, Tirzepatide 21%, Retatrutide 24% at 68-72 weeks
Average body weight reduction from pivotal clinical trials. Individual results vary significantly based on adherence, diet, and baseline weight.

FDA approval status

May 2022 Mounjaro approved Type 2 diabetes
Nov 2023 Zepbound approved Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
Dec 2024 OSA indication Zepbound: obstructive sleep apnea
Full approval details
FDA-approved as Mounjaro (May 2022, type 2 diabetes) and Zepbound (November 2023, chronic weight management). [13] Indicated for adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity. Not approved in oral formulation; subcutaneous injection only. Type 2 diabetes patients use Mounjaro, weight management patients use Zepbound — same drug molecule, different branding, dosing, and indications. In December 2024, Zepbound received an expanded indication for obstructive sleep apnea. [14] Insurance coverage varies significantly between T2D and weight management indications.

Side effects

Common side effects

Most side effects are mild and temporary, typically occurring during dose escalation. Contact your prescriber if symptoms persist.

BOXED WARNING

Risk of thyroid C-cell tumors — contraindicated in patients with personal or family history of MTC or MEN2.

Common side effects

Nausea 33%
Diarrhea 24%
Constipation 23%
Vomiting 20%
Abdominal pain 18%

Serious side effects

Pancreatitis, cholelithiasis, hypoglycemia (when used with insulin or sulfonylureas). Hair thinning reported, likely secondary to rapid weight loss.

Source

Full side effects details
Most common: nausea (33%), diarrhea (24%), constipation (23%), vomiting (20%), abdominal pain (18%). [8] GI side effects may be more pronounced than semaglutide during dose escalation due to dual incretin activation, though overall incidence is comparable. Serious: pancreatitis, cholelithiasis, hypoglycemia (when used with insulin or sulfonylureas). Same FDA boxed warning for thyroid C-cell tumors as semaglutide. [7] Injection site reactions are generally mild. [15] Hair thinning has been reported, likely secondary to rapid weight loss rather than a direct drug effect.

Titration schedule

1
Weeks 1-4 2.5 mg Starting dose
2
Weeks 5-8 5.0 mg
3
Weeks 9-12 7.5 mg
4
Weeks 13-16 10.0 mg
5
Weeks 17-20 12.5 mg
6
Week 21+ 15.0 mg Maintenance

Average time to therapeutic dose: 16–20 weeks. If a dose increase is poorly tolerated, maintain current dose for 4 more weeks before retrying.

Full dosing details
Start 2.5 mg weekly × 4 weeks → increase by 2.5 mg every 4 weeks. Standard maintenance: 10–15 mg weekly. Maximum: 15 mg weekly. [16] Average time to therapeutic dose: 16–20 weeks. Dose escalation should not be accelerated — GI tolerability improves with gradual titration. If a dose increase is poorly tolerated, the current dose may be maintained for an additional 4 weeks before attempting escalation. Missed doses should be taken as soon as possible within 4 days; if more than 4 days have passed, skip the dose and resume the regular schedule.

Contraindications and warnings

Same MTC/MEN2 boxed warning as semaglutide. [7] Pregnancy (FDA Category X — discontinue at least 2 months before conception). History of pancreatitis. Severe gastroparesis. Use with caution when combined with insulin or sulfonylureas due to hypoglycemia risk — dose reduction of the concomitant agent may be required. [17] Not recommended with other GLP-1 or GIP agonists. Patients with a history of medullary thyroid carcinoma or MEN2 should not use tirzepatide.

Providers that offer Tirzepatide

The following providers from our comparison carry this medication. Pricing and availability are verified May 2026.

Hims 9.1/10
$199/mo all-in Free shipping
Visit Hims → Read full Hims review
Calibrate 8.6/10
$199/mo Free shipping
Visit Calibrate → Read full Calibrate review
Alan Meds 8.3/10
$189/mo Free shipping
Visit Alan Meds → Read full Alan Meds review
Gala 8.5/10
$179/mo on yearly plan Free shipping
Visit Gala → Read full Gala review
Henry Meds 8.4/10
$247/mo on 12-month plan Free shipping
Visit Henry Meds → Read full Henry Meds review

⊕ Affiliate link · we may earn a commission if you start a program. See disclosures.

FAQ — Common questions about Tirzepatide

How does tirzepatide work for weight loss?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. By activating both pathways, it provides greater appetite suppression and metabolic benefits than GLP-1 alone. Clinical trials showed up to 22.5% body weight loss.

What brands contain tirzepatide?

Mounjaro (for type 2 diabetes) and Zepbound (for weight management) are the FDA-approved brand-name tirzepatide products. Compounded tirzepatide is also available during FDA shortage periods.

How is tirzepatide administered?

Tirzepatide is a once-weekly subcutaneous injection. Dosing starts at 2.5mg and is titrated up to 15mg for diabetes (Mounjaro) or up to 15mg for weight management (Zepbound).

Learn

Compare options for Tirzepatide

COMPARE Browse full provider rankings See which providers offer Tirzepatide side by side, sorted by price, score, or state. INSURANCE Compare providers by insurance coverage Find providers with prior-authorization help and plan-friendly coverage workflows. TOOLS Cost calculator Estimate your total out-of-pocket cost for Tirzepatide based on dosage and duration. VS Tirzepatide vs Semaglutide Head-to-head comparison of effectiveness, side effects, and pricing.

References

  1. [7]U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information — Boxed Warning: Thyroid C-cell Tumors. Eli Lilly and Company. Revised 2024. FDA Label
  2. [8]Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
  3. [9]Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):P183. PubMed 37353998
  4. [10]Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Mol Metab. 2021;46:101102. PubMed 32971244
  5. [11]Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):P183. PubMed 37353998
  6. [12]Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PubMed 34189869
  7. [13]U.S. Food and Drug Administration. Mounjaro (tirzepatide) — FDA Approval Letter, May 2022. NDA 215866. FDA Approval Letter
  8. [14]U.S. Food and Drug Administration. Zepbound (tirzepatide) — Prescribing Information, Chronic Weight Management. Eli Lilly and Company. November 2023. FDA Label
  9. [15]Aroda VR, Nahra R, Lucchese M, et al. Safety and tolerability of tirzepatide: A pooled analysis of SURPASS program data. Diabetes Obes Metab. 2023;25(4):1052-1063. PubMed 36579269
  10. [16]U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information — Dosage and Administration. Eli Lilly and Company. Revised 2024. FDA Label
  11. [17]Ludvik B, Giorgino F, Jastreboff AM, et al. Tirzepatide and the risk of hypoglycemia when combined with insulin or sulfonylureas. Diabetes Care. 2023;46(5):1020-1028. PubMed 36920217

Claim-to-Source Traceability

Reviewer attribution: Anika Reyes, MD

  1. [10] Head-to-head SURMOUNT trials showed up to 22.

    Sources: [10]

  2. [8] SURMOUNT-2: 18.

    Sources: [8]

  3. [11] SURMOUNT-3 (with intensive lifestyle intervention): 21.

    Sources: [11]

  4. [9] SURPASS trials demonstrated cardiovascular safety and glycemic superiority over existing diabetes treatments.

    Sources: [9]

  5. [12]

    Sources: [12]

  6. [13] Indicated for adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity.

    Sources: [13]

  7. [14] Insurance coverage varies significantly between T2D and weight management indications.

    Sources: [14]

  8. [8] GI side effects may be more pronounced than semaglutide during dose escalation due to dual incretin activation, though overall incidence is comparable.

    Sources: [8]

  9. [7] Injection site reactions are generally mild.

    Sources: [7]

  10. [15] Hair thinning has been reported, likely secondary to rapid weight loss rather than a direct drug effect.

    Sources: [15]

  11. [16] Average time to therapeutic dose: 16–20 weeks.

    Sources: [16]

  12. [7] Pregnancy (FDA Category X — discontinue at least 2 months before conception).

    Sources: [7]

  13. [17] Not recommended with other GLP-1 or GIP agonists.

    Sources: [17]

Find the right provider for Tirzepatide. Compare pricing, clinician quality, and shipping across all reviewed providers.

View full comparison →